csirt@kutim:~/threat-intel/cve/CVE-2026-47390

Katalog CVE

CVSS 5.5 · Medium EPSS 0,18%

Kerentanan Server-Side Request Forgery (SSRF). Skor CVSS 3.1 5.5 (Medium) menurut github.com.

Deskripsi (NVD)

PraisonAI is a multi-agent teams system. Prior to version 4.6.40 of PraisonAI, corresponding to version 1.6.40 of praisonaiagents, `spider_tools` URL validation can be bypassed using alternate loopback host encodings. The tool contains a URL validation function intended to block local or unsafe targets before fetching attacker-controlled URLs. However, the validation only blocks a small set of exact host strings such as `localhost` and `127.0.0.1`. It does not normalize hostnames, resolve DNS, parse numeric IPv4 variants, or validate the final resolved IP address before making the request. As a result, certain URLs may bypass the protection and still reach loopback services. After the weak validation passes, `scrape_page()` calls `requests.Session.get()` on the attacker-controlled URL. This allows an attacker who can influence URLs passed to `scrape_page`, `crawl`, or `extract_text` to induce SSRF requests against loopback-only services. This is a server-side request forgery protection bypass. PraisonAI version 4.6.40 and praisonaiagents version 1.6.40 contain a patch.

Rincian

Terbit di NVD
21 Juli 2026
Terakhir diubah
22 Juli 2026
Status NVD
Deferred
CVSS 3.1
5.5 (Medium), sumber github.com
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:N/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-918: Server-Side Request Forgery (SSRF)
EPSS (30 hari)
0,18% peluang dieksploitasi; lebih tinggi dari 6,4% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.